Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.

Several other analysts also recently issued reports on DPLO. Bank of America Corporation boosted their price target on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a research note on Thursday, May 25th. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Needham & Company LLC initiated coverage on Diplomat Pharmacy in a research note on Friday, July 21st. They issued a “buy” rating and a $19.75 price target for the company. Finally, TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $17.89.

Diplomat Pharmacy (DPLO) opened at 19.50 on Friday. The company has a 50 day moving average price of $16.57 and a 200-day moving average price of $16.18. Diplomat Pharmacy has a 52 week low of $12.25 and a 52 week high of $31.34. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of 106.56 and a beta of 0.65.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 EPS. Equities analysts predict that Diplomat Pharmacy will post $0.75 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/14/bidaskclub-upgrades-diplomat-pharmacy-inc-dplo-to-hold.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in DPLO. JPMorgan Chase & Co. raised its holdings in Diplomat Pharmacy by 73.1% in the 1st quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after acquiring an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Diplomat Pharmacy by 80.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after acquiring an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after acquiring an additional 2,794 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Diplomat Pharmacy by 13.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after acquiring an additional 1,073 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its holdings in Diplomat Pharmacy by 4.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after acquiring an additional 480 shares in the last quarter. 69.89% of the stock is owned by hedge funds and other institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.